BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

GlobalData’s director of therapy research & analysis in medical devices says the new entity could make an attractive ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

According to the company, medical essentials and interventional lead the medical technology unit's business lines, bringing ...

BD (NYSE: BDX) announced that its board unanimously authorized management to pursue the separation of its Life Sciences ...

Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions ...

BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic ...

As the company pursues this transaction, BD will remain focused on execution and continue to operate the Biosciences and Diagnostic Solutions business and the other BD businesses in alignment with ...